Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
376 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016', provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - The report reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics and enlists all their major and minor projects - The report assesses Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Overview 9 Therapeutics Development 10 Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview 10 Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Comparative Analysis 11 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics under Development by Companies 12 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics under Investigation by Universities/Institutes 15 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Products under Development by Companies 19 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Products under Investigation by Universities/Institutes 23 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development 24 4SC AG 24 AbbVie Inc 25 Acetylon Pharmaceuticals, Inc. 26 Actinium Pharmaceuticals, Inc. 27 ADC Therapeutics Sarl 28 Affimed GmbH 29 Amgen Inc. 30 Arno Therapeutics, Inc. 31 Bellicum Pharmaceuticals, Inc. 32 Bristol-Myers Squibb Company 33 Celgene Corporation 34 Cell Medica Limited 35 Cellular Biomedicine Group, Inc. 36 Constellation Pharmaceuticals, Inc. 37 Curis, Inc. 38 Faron Pharmaceuticals Oy 39 Gamida Cell Ltd. 40 Incyte Corporation 41 Merck & Co., Inc. 42 Merck KGaA 43 Mesoblast Limited 44 Millennium Pharmaceuticals Inc 45 Mirati Therapeutics Inc. 46 Molecular Templates Inc. 47 NantKwest, Inc. 48 Ono Pharmaceutical Co., Ltd. 49 Pfizer Inc. 50 Philogen S.p.A. 51 Polyphor Ltd. 52 Rich Pharmaceuticals, Inc. 53 Seattle Genetics, Inc. 54 Selvita S.A. 55 Sigma-Tau S.p.A. 56 Spectrum Pharmaceuticals, Inc. 57 Stemline Therapeutics, Inc. 58 Taiwan Liposome Company, Ltd. 59 Takeda Pharmaceutical Company Limited 60 TG Therapeutics, Inc. 61 Theravectys SA 62 TRACON Pharmaceuticals, Inc. 63 Trillium Therapeutics Inc. 64 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment 65 Assessment by Monotherapy Products 65 Assessment by Combination Products 66 Assessment by Target 67 Assessment by Mechanism of Action 72 Assessment by Route of Administration 78 Assessment by Molecule Type 80 Drug Profiles 82 (INCB-039110 + INCB-040093) - Drug Profile 82 ADCT-301 - Drug Profile 83 AFM-13 - Drug Profile 84 Alocrest - Drug Profile 88 AR-42 - Drug Profile 90 avelumab - Drug Profile 92 azacitidine - Drug Profile 97 balixafortide - Drug Profile 102 BC-8Y90 - Drug Profile 104 BMS-986016 - Drug Profile 105 BPX-501 - Drug Profile 107 brentuximab vedotin - Drug Profile 111 CBM-C30.1 - Drug Profile 135 Cellular Immunotherapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile 136 Cellular Immunotherapy for Oncology - Drug Profile 137 Cellular Immunotherapy for Oncology - Drug Profile 138 Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile 139 Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile 140 Cellular Immunotherapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile 141 Cellular Immunotherapy to Target GM-CSF for Solid Tumor and Hematological Cancer - Drug Profile 142 Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile 143 Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 144 Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile 145 CMD-003 - Drug Profile 146 CPI-0610 - Drug Profile 148 CUDC-907 - Drug Profile 149 Epstein-Barr virus vaccine - Drug Profile 154 Ferritarg - Drug Profile 155 FP-1305 - Drug Profile 156 haNK Program - Drug Profile 158 ibrutinib - Drug Profile 159 INCB-40093 - Drug Profile 184 Indimitecan - Drug Profile 185 Indotecan hydrochloride - Drug Profile 186 Iomab-B - Drug Profile 187 ipilimumab - Drug Profile 192 ixazomib citrate - Drug Profile 200 lirilumab - Drug Profile 209 MK-2206 - Drug Profile 213 mocetinostat - Drug Profile 216 Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 221 MPC-CBE - Drug Profile 222 MT-17000 - Drug Profile 224 NiCord - Drug Profile 225 nivolumab - Drug Profile 228 NL-101 - Drug Profile 256 ONX-0801 - Drug Profile 258 pembrolizumab - Drug Profile 260 PF-06801591 - Drug Profile 291 PNK-007 - Drug Profile 292 procarbazine hydrochloride - Drug Profile 293 radretumab - Drug Profile 294 resminostat - Drug Profile 296 ricolinostat - Drug Profile 306 RP-323 - Drug Profile 314 ruxolitinib phosphate - Drug Profile 316 sapanisertib - Drug Profile 328 SEA-CD40 - Drug Profile 331 SEL-24B489 - Drug Profile 332 SL-101 - Drug Profile 333 SL-501 - Drug Profile 334 Small Molecule to Inhibit ADAM-10 for Hodgkin Lymphoma - Drug Profile 335 temsirolimus - Drug Profile 336 TGR-1202 - Drug Profile 338 TRC-102 - Drug Profile 345 TTI-621 - Drug Profile 347 Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile 350 vinorelbine tartrate - Drug Profile 351 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects 352 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products 356 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones 357 Featured News & Press Releases 357 Appendix 370 Methodology 370 Coverage 370 Secondary Research 370 Primary Research 370 Expert Panel Validation 370 Contact Us 370 Disclaimer 371
List of Tables
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2016 15 Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Comparative Analysis, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Comparative Analysis by Late Stage Development, H2 2016 21 Comparative Analysis by Clinical Stage Development, H2 2016 22 Comparative Analysis by Early Stage Development, H2 2016 23 Products under Development by Companies, H2 2016 24 Products under Development by Companies, H2 2016 (Contd..1) 25 Products under Development by Companies, H2 2016 (Contd..2) 26 Products under Development by Companies, H2 2016 (Contd..3) 27 Products under Investigation by Universities/Institutes, H2 2016 28 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by 4SC AG, H2 2016 29 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AbbVie Inc, H2 2016 30 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 31 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 32 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ADC Therapeutics Sarl, H2 2016 33 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Affimed GmbH , H2 2016 34 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Amgen Inc., H2 2016 35 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Arno Therapeutics, Inc., H2 2016 36 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 37 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bristol-Myers Squibb Company, H2 2016 38 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celgene Corporation, H2 2016 39 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cell Medica Limited, H2 2016 40 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016 41 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016 42 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Curis, Inc., H2 2016 43 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Faron Pharmaceuticals Oy, H2 2016 44 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Gamida Cell Ltd., H2 2016 45 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Incyte Corporation, H2 2016 46 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck & Co., Inc., H2 2016 47 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck KGaA, H2 2016 48 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mesoblast Limited, H2 2016 49 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 50 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mirati Therapeutics Inc., H2 2016 51 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Molecular Templates Inc., H2 2016 52 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by NantKwest, Inc., H2 2016 53 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 54 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Pfizer Inc., H2 2016 55 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Philogen S.p.A., H2 2016 56 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Polyphor Ltd., H2 2016 57 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rich Pharmaceuticals, Inc., H2 2016 58 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Seattle Genetics, Inc., H2 2016 59 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Selvita S.A., H2 2016 60 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Sigma-Tau S.p.A., H2 2016 61 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 62 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Stemline Therapeutics, Inc., H2 2016 63 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 64 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 65 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by TG Therapeutics, Inc., H2 2016 66 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Theravectys SA, H2 2016 67 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by TRACON Pharmaceuticals, Inc., H2 2016 68 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Trillium Therapeutics Inc., H2 2016 69 Assessment by Monotherapy Products, H2 2016 70 Assessment by Combination Products, H2 2016 71 Number of Products by Stage and Target, H2 2016 73 Number of Products by Stage and Mechanism of Action, H2 2016 78 Number of Products by Stage and Route of Administration, H2 2016 83 Number of Products by Stage and Molecule Type, H2 2016 85 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H2 2016 356 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects (Contd..1), H2 2016 357 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects (Contd..2), H2 2016 358 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects (Contd..3), H2 2016 359 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, H2 2016 360
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
